1.	Stem Cell Transplant for Hematological Malignancy Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
2.	Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
3.	Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 04-21, NCT01241500
4.	Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 709, U01HL069294, U01HL069294-05, 0901, NCT01339910
5.	PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: PRO#1278: Flu-Bu-TBI, NCT01366612
6.	Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 60 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: CLTR0310-301, NCT01696084
7.	Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2012-0737, NCT01787487
8.	Phase I/II Pilot Study of Non-Myeloablative Chemotherapy Followed By Allogeneic Stem Cell Transplantation in Pediatric Patients With Hematopoietic Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 4 to 21 Sponsor: NCI Protocol IDs: NCI-01-C-0125F, NCT00020592
9.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
10.	Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: CB001, UMN-2003LS055, UMN-MT2003-20, VIACELL-CB001-03, UMN-0310M3141, NCT00089596
11.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
12.	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
13.	Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
14.	Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
15.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
16.	Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-0132, NCT00943319
17.	PKC412 and 5-Azacytidine Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0374, NCT01202877
18.	Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 6 montha to 70 Sponsor: Other Protocol IDs: J1055, NA_00039823, NCT01203722
19.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
20.	Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0788, NCT01289457
21.	Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 6 months to 85 Sponsor: Other Protocol IDs: J1151, NA_00048378, NCT01342289
22.	Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RGI-2001-02, NCT01379209
23.	Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-001, NCT01416428
24.	Improving Blood Stem Cell Collection and Transplant Procedures Phase: Phase II, Phase I Type: Treatment Status: Active Age: 3 to 79 Sponsor: NHLBI Protocol IDs: 120028, 12-H-0028, NCT01517035
25.	CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 2012-0265, NCT01664910